Related Experiment Videos
Development of dinitrochlorobenzene contact hypersensitivity in rat submaxillary salivary gland
Abstract:
Stimulation of cell-mediated immunity (CMI) by 2,4 dinitrochlorobenzene (DNCB) was reported to be effective in clinical regression of some carcinomas and precancerous lesions. This study investigated development of CMI in rat submaxillary salivary glands with dermal application of DNCB to provide a model for the study of immunotherapy in salivary gland neoplasia. Twenty rats received 0.02 ml of 0.5% DNCB in 4:1 acetone corn-oil applied with a glass rod to 3 cm2 of clipped ventral skin of the neck covering the submaxillary salivary gland on 2 successive days. Ten days later, the submaxillary glands were challenged with an injection of 0.02 ml of DNCB. Thirty-two h later the animals were killed and the glands examined grossly and microscopically. Thirty control animals were sensitized and challenged, (a) 10 with 0.5% DNCB, then vehicle only, (b) 10 with vehicle only, then 0.5% DNCB, and (c) 10 with vehicle both times. Gross examination of experimental and control glands disclosed moderate edema and congestion. Microscopically, experimental glands showed inflammatory changes including infiltration, vascular congestion and perivascular cuffing of lymphocytes. Regional lymph nodes showed proliferation of cortical germinal centers only. Control glands showed acute vascular congestion in group (a), and absence of microscopic features of delayed hypersensitivity.
Insights
This study shows 2,4 dinitrochlorobenzene (DNCB) induces cell-mediated immunity (CMI) in rat salivary glands, creating a model for salivary gland cancer immunotherapy research.
Area of Science:
- Immunology
- Oncology
- Dermatology
Background:
- Cell-mediated immunity (CMI) stimulation via 2,4 dinitrochlorobenzene (DNCB) has shown efficacy in regressing certain carcinomas and precancerous lesions.
- Developing a reliable animal model is crucial for studying immunotherapy in salivary gland neoplasia.
Purpose of the Study:
- To investigate the development of CMI in rat submaxillary salivary glands using dermal DNCB application.
- To establish a preclinical model for evaluating immunotherapy strategies against salivary gland tumors.
Main Methods:
- Rats received dermal application of 0.5% DNCB on the neck for two consecutive days to sensitize the submaxillary salivary glands.
- Ten days post-sensitization, glands were challenged with a DNCB injection.
- Glands and regional lymph nodes were examined grossly and microscopically 32 hours after challenge.
Main Results:
- Experimental glands exhibited moderate edema, congestion, and microscopic inflammatory changes, including lymphocytic infiltration and perivascular cuffing.
- Regional lymph nodes displayed proliferation of cortical germinal centers.
- Control groups showed varying degrees of vascular congestion or no significant hypersensitivity features.
Conclusions:
- Dermal DNCB application successfully induced a delayed hypersensitivity response in rat submaxillary salivary glands.
- This model effectively mimics inflammatory responses relevant to CMI, supporting its use for immunotherapy studies in salivary gland neoplasia.